1. Home
  2. TALO vs RAPP Comparison

TALO vs RAPP Comparison

Compare TALO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

N/A

Current Price

$16.65

Market Cap

2.6B

Sector

Energy

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

N/A

Current Price

$33.51

Market Cap

2.3B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TALO
RAPP
Founded
2011
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
TALO
RAPP
Price
$16.65
$33.51
Analyst Decision
Buy
Strong Buy
Analyst Count
10
13
Target Price
$19.89
★ $62.88
AVG Volume (30 Days)
★ 1.7M
403.7K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.34
EPS
★ N/A
N/A
Revenue
★ $1,780,070,000.00
N/A
Revenue This Year
$26.70
N/A
Revenue Next Year
$4.70
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$8.97
$23.75
52 Week High
$18.73
$52.93

Technical Indicators

Market Signals
Indicator
TALO
RAPP
Relative Strength Index (RSI) 45.86 29.65
Support Level $16.01 $33.15
Resistance Level $17.23 $40.61
Average True Range (ATR) 0.56 2.53
MACD -0.16 -0.75
Stochastic Oscillator 10.26 19.11

Price Performance

Historical Comparison
TALO
RAPP

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: